0690.HK - Uni-Bio Science Group Limited

HKSE - HKSE Delayed Price. Currency in HKD
0.074
0.000 (0.00%)
At close: 3:55PM HKT
Stock chart is not supported by your current browser
Previous Close0.074
Open0.076
Bid0.073 x 0
Ask0.074 x 0
Day's Range0.073 - 0.076
52 Week Range0.070 - 0.156
Volume840,000
Avg. Volume2,663,585
Market Cap457.318M
Beta (3Y Monthly)-0.07
PE Ratio (TTM)N/A
EPS (TTM)-0.012
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-08-22
1y Target EstN/A
  • Reuters4 days ago

    BRIEF-Uni-Bio Science Group Says Unit In Cooperation Agreement For Pinup National Promotion Project

    Dec 10 (Reuters) - Uni-Bio Science Group Ltd: * UNIT ENTERED COOPERATION AGREEMENT FOR PINUP® NATIONAL PROMOTION PROJECT WITH SHANGHAI LOYMED PHARMA TECHNOLOGY CO Source text for Eikon: Further company ...

  • Reuters28 days ago

    BRIEF-Uni-Bio Science Group Says Unit To Sell To Figures Up Sale Shares For RMB40 Mln

    Nov 16 (Reuters) - Uni-Bio Science Group Ltd: * UNIT TO SELL TO FIGURES UP SALE SHARES FOR RMB40 MILLION TO GREATER BAY (R&D) CAPITAL * UNIT TO SELL WTGL LAND AND PROPERTY RIGHTS & WTGL SALE SHARES FOR ...

  • PR Newswire4 months ago

    Uni-Bio Science Group Limited Announces 2018 Interim Results

    HONG KONG, Aug. 25, 2018 /PRNewswire/ -- A fully integrated biopharmaceutical company -- Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its interim results for the period ended 30 June 2018 (the "Period" or "1H2018"), as well as its comparatively figures for the six months ended 30 June 2017 ("1H2017"). During the Period, the Group's marketed products, namely GeneTime®, GeneSoft®, Pinup® and Bokangtai have made steady progress respectively, while solid accomplishments have been achieved for the products in pipeline. During the Period, the Group also fostered the strategic cooperation with Beijing Baiao Pharmaceutical Co., Ltd ("Beijing Baiao") to jointly develop and market the Acarbose tablets project.

  • PR Newswire4 months ago

    Uni-Bio Science Group Limited Announces 2018 Interim Results

    HONG KONG, Aug. 24, 2018 /PRNewswire/ -- A fully integrated biopharmaceutical company -- Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its interim results for the period ended 30 June 2018 (the "Period" or "1H2018"), as well as its comparatively figures for the six months ended 30 June 2017 ("1H2017"). During the Period, the Group's marketed products, namely GeneTime®, GeneSoft®, Pinup® and Bokangtai have made steady progress respectively, while solid accomplishments have been achieved for the products in pipeline. During the Period, the Group also fostered the strategic cooperation with Beijing Baiao Pharmaceutical Co., Ltd ("Beijing Baiao") to jointly develop and market the Acarbose tablets project.

  • Reuters4 months ago

    BRIEF-Uni-Bio Science Group Posts Hy Loss For Period Of Hk$63.2 Mln

    Aug 24 (Reuters) - Uni-Bio Science Group Ltd: * HY REVENUE HK$59.6 MILLION VERSUS HK$62.9 MILLION * HY LOSS FOR PERIOD HK$63.2 MILLION VERSUS LOSS OF HK$33.7 MILLION Source text for Eikon: Further company ...

  • Reuters6 months ago

    BRIEF-Uni-Bio Science Group Announces Strategic Cooperation Agreement With Beijing Baiao Pharmaceutical

    June 5 (Reuters) - Uni-Bio Science Group Ltd: * UNIT AND BEIJING BAIAO PHARMACEUTICAL CO., LTD. ENTERED STRATEGIC COOPERATION AGREEMENT * AGREEMENT REGARDING JOINT DEVELOPMENT AND PROMOTIONAL MARKETING ...

  • PR Newswire6 months ago

    Mr. Winston Xue, General Manager of Uni-Bio Science Healthcare Limited Was Interviewed by Bioon.com

    During the interview, Mr. Xue shared his insights on the unique transformation and development path of the innovative pharmaceutical enterprise based in Hong Kong, as well as updates of the latest research progress and future marketing model of the Group. The interview was published on May 24, 2018.

  • PR Newswire6 months ago

    Mr. Winston Xue, General Manager of Uni-Bio Science Healthcare Limited Was Interviewed by Bioon.com

    During the interview, Mr. Xue shared his insights on the unique transformation and development path of the innovative pharmaceutical enterprise based in Hong Kong, as well as updates of the latest research progress and future marketing model of the Group. The interview was published on May 24, 2018.

  • Who Are The Major Shareholders Of Uni-Bio Science Group Limited (HKG:690)?
    Simply Wall St.8 months ago

    Who Are The Major Shareholders Of Uni-Bio Science Group Limited (HKG:690)?

    Today, I will be analyzing Uni-Bio Science Group Limited’s (SEHK:690) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure has been found to have an impactRead More...

  • PR Newswire9 months ago

    Uni-Bio Science Group Limited Posts Its 2017 Annual Results

    HONG KONG, March 30, 2018 /PRNewswire/ -- A leading integrated biopharmaceutical researcher, developer and manufacturer Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2017 (the "Year"). During the Year, the Group's marketed products, namely GeneTime®, GeneSoft®, Pinup® and Bokangtai have recorded satisfactory performance. Successfully transferred the distribution of GeneSoft® to China Resources Zizhu Pharmaceutical Co., Ltd., which has broadened the hospital coverage and achieved significant savings in sales and distribution expenses.

  • PR Newswire9 months ago

    Uni-Bio Science Group Limited Posts Its 2017 Annual Results

    HONG KONG, March 30, 2018 /PRNewswire/ -- A leading integrated biopharmaceutical researcher, developer and manufacturer Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2017 (the "Year"). During the Year, the Group's marketed products, namely GeneTime®, GeneSoft®, Pinup® and Bokangtai have recorded satisfactory performance. Successfully transferred the distribution of GeneSoft® to China Resources Zizhu Pharmaceutical Co., Ltd., which has broadened the hospital coverage and achieved significant savings in sales and distribution expenses.

  • Reuters9 months ago

    BRIEF-Uni-Bio Science Group Posts Loss For Year Of HK$279.3 Mln

    March 29 (Reuters) - Uni-Bio Science Group Ltd: * FY REVENUE HK$156.5 MILLION VERSUS HK$146.5 MILLION * FY LOSS FOR YEAR HK$279.3 MILLION VERSUS LOSS HK$55.7 MILLION Source text for Eikon: Further company ...